• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[主动免疫前后感染中的流行过程。II. 自然流行期间人群中易感个体数量的变化及其通过主动免疫的控制]

[The epidemic process in infections before and after active immunization. II. Changes in the number of susceptible individuals in the population during a natural epidemic and its control by active immunization].

作者信息

Mimra J, Farník J

机构信息

Okresní hygienická stanice Sokolov.

出版信息

Cesk Epidemiol Mikrobiol Imunol. 1993 Mar;42(1):7-11.

PMID:8485774
Abstract

Based on the long-term follow-up of the incidence of some infectious diseases in the district and calculations of the actual number of infected subjects, the authors present an estimate of the ratio of susceptible and immune subjects during the unimpaired epidemic process. The epidemic process develops from the lowest range of immune subjects and stops at the highest range. The highest range thus gives the ratio of immune subjects which must be achieved or maintained by active immunization to achieve elimination of a given infection. The authors demonstrate on the model infection the mechanism by which after immunization the shift of infections to higher age groups occurs, and during introduction of the infection not only contact infections occur, but epidemic incidence develops. The restoration of some infections after years of elimination is to a restricted extent a natural phenomenon and does not imply failure of active immunization.

摘要

基于对该地区一些传染病发病率的长期跟踪以及对实际感染病例数的计算,作者给出了在未受干扰的流行过程中易感人群与免疫人群比例的估计值。流行过程从免疫人群的最低比例开始发展,并在最高比例时停止。因此,最高比例给出了必须通过主动免疫来达到或维持的免疫人群比例,以实现消除特定感染。作者在模型感染中证明了免疫后感染向更高年龄组转移的机制,并且在引入感染时不仅会发生接触性感染,还会出现流行发病率。经过数年消除后某些感染的再次出现,在一定程度上是一种自然现象,并不意味着主动免疫失败。

相似文献

1
[The epidemic process in infections before and after active immunization. II. Changes in the number of susceptible individuals in the population during a natural epidemic and its control by active immunization].[主动免疫前后感染中的流行过程。II. 自然流行期间人群中易感个体数量的变化及其通过主动免疫的控制]
Cesk Epidemiol Mikrobiol Imunol. 1993 Mar;42(1):7-11.
2
[The epidemic process in infections before and after active immunization. I. Comparison of long-term monitoring of the disease with a simple mathematical model].
Cesk Epidemiol Mikrobiol Imunol. 1993 Mar;42(1):3-6.
3
[The determination of susceptibility to measles, rubella, mumps and chickenpox in students of health-related areas].[卫生相关专业学生对麻疹、风疹、腮腺炎和水痘易感性的测定]
Acta Med Port. 1999 Apr-Jun;12(4-6):155-60.
4
[Overview of measles, mumps, rubella and varicella vaccination in adolescents and adults].[青少年及成人麻疹、腮腺炎、风疹和水痘疫苗接种概述]
Dtsch Med Wochenschr. 2009 Apr;134 Suppl 2:S77-81. doi: 10.1055/s-0029-1220214. Epub 2009 Apr 7.
5
Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.2001年美国7种儿童常规免疫接种疫苗时间表的经济学评估
Arch Pediatr Adolesc Med. 2005 Dec;159(12):1136-44. doi: 10.1001/archpedi.159.12.1136.
6
[Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].[波兰人群中麻疹、腮腺炎和风疹抗体及疫苗接种情况]
Przegl Epidemiol. 2003;57(2):281-8.
7
[The present epidemiologic status and prognosis in measles].[麻疹的当前流行病学状况及预后]
Cesk Epidemiol Mikrobiol Imunol. 1992 Sep;41(4):210-4.
8
Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.麻疹-腮腺炎-风疹-水痘疫苗1剂次和2剂次接种方案的水痘免疫原性
J Infect Dis. 2008 Mar 1;197 Suppl 2:S152-5. doi: 10.1086/522126.
9
Healthcare workers and immunity to infectious diseases.医护人员与传染病免疫力。
Aust N Z J Public Health. 2008 Aug;32(4):367-71. doi: 10.1111/j.1753-6405.2008.00257.x.
10
Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.韩国麻疹和腮腺炎的血清流行病学:强化免疫活动对麻疹免疫力的影响。
Vaccine. 2004 Dec 2;23(3):290-7. doi: 10.1016/j.vaccine.2004.07.030.